Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Lancet Oncol. 2015 Jun 23;16(8):908–918. doi: 10.1016/S1470-2045(15)00083-2

Figure 2: Kaplan-Meier estimates of progression-free survival assessed in the intention-to-treat population.

Figure 2:

Kaplan-Meier curves for RECIST v1.1-assessed progression by independent central review (A), RECIST v1.1, by investigator review (B), and modified RECIST v1.1, by investigator review (C). RECIST v1.1=Response Evaluation Criteria in Solid Tumors, version 1.1.